Phase 2 Study of Weekly Bortezomib in Mantle Cell and Follicular Lymphoma

Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, p = 0.02) with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gerecitano, John, Portlock, Carol, Moskowitz, Craig, Hamlin, Paul, Straus, David, Zelenetz, Andrew D., Zhang, Zhigang, Dumitrescu, Otilia, Debra, Sarasohn, Lin, Dorothy, Pappanicholaou, Jennifer, Cortelli, Barbara MacGregor, Neylon, Ellen, Hamelers, Rachel, Wright, John, O'Connor, Owen A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2009
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4035037/
https://ncbi.nlm.nih.gov/pubmed/19624539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07775.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares